People with chronic Crohn’s disease, especially those who have not responded to conventional therapy, should be treated with infliximab or adalimumab, the National Institute for Clinical Excellence (NICE) has recommended.
A draft guidance paper by the organisation also suggests infliximab as a treatment option for adults with active, fistulising Crohn’s disease, and for children and young people aged 6-17 years old with severe forms of the condition.
Nice said the two drugs represented the most cost-effective means of controlling Crohn’s, for which scientists are no closer to finding a cure.
“Our review of the evidence indicates that infliximab and adalimumab are clinically and cost effective treatment options for people with the most severe forms of Crohn’s disease, and for whom conventional treatments have failed or are not an option,” Dr Carole Longson, Health Technology Evaluation Centre Director said.
“There is no known cure for this debilitating condition, so treatment is limited to controlling and easing symptoms.”
Copyright Press Association 2010
National Institute for Clinical Excellence